Pittsburgh-based company behind ‘promising’ new COVID-19 treatment
On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.” The Department of Community and Economic Development will announce that Pittsburgh-based biotechnology company CytoAgents has begun its Phase 1 clinical trial for COVID-19 treatment. Read more >>